18F-HER2 PET in Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma.
Launched by FIRST AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY · Aug 2, 2023
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new imaging technique called 18F-HER2 PET to see how well it can help doctors evaluate the effectiveness of anti-HER2 therapy for patients with urothelial carcinoma, a type of bladder cancer. The trial aims to understand if this imaging method can provide useful information about how well the treatment is working. It is an open-label study, which means that both the researchers and participants will know the treatment being given.
To be eligible for this trial, participants need to be between 30 and 80 years old and have locally advanced or advanced urothelial carcinoma. They must also be planning to receive anti-HER2 treatment and be able to provide informed consent, which means they understand the study and agree to participate. However, individuals with other active cancers, severe health issues, certain mental disorders, or those who cannot follow the research guidelines will not be able to join. If you participate, you can expect to undergo PET scans as part of the study to help assess the treatment’s effectiveness. This trial is not yet recruiting participants, but it represents an important step in improving treatment options for bladder cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Informed consent document must be signed.
- • 2. Aged 30-80 years old, both genders.
- • 3. Patients with locally advanced or advanced urothelial carcinoma
- • 4. Patients plan to undergo anti HER2 treatment.
- Exclusion Criteria:
- • 1. Subjects with active malignancies other than urothelial carcinoma within 5 years should be excluded.
- • 2. Patients with severe liver, kidney, and hematopoietic diseases
- • 3. Patients with other mental disorders or primary emotional disorders
- • 4. Those who are unable to understand, comply with the research protocol, or sign an informed consent form
- • 5. PET imaging Contraindication (including pregnant women, lactating women, women of childbearing age who have a recent fertility plan, etc.)
- • 6. Individuals who are allergic to imaging agents
- • 7. Hypoglycemic reactions, severe pain, etc. cannot be accompanied by PET scans
About First Affiliated Hospital Of Zhejiang University
The First Affiliated Hospital of Zhejiang University is a leading medical institution located in Hangzhou, China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive network of specialists and state-of-the-art facilities to facilitate groundbreaking studies across various medical disciplines. With a focus on improving patient outcomes and contributing to global medical knowledge, the hospital actively engages in collaborative research initiatives, ensuring rigorous adherence to ethical standards and regulatory compliance. Its dedication to fostering a culture of scientific inquiry underscores its role as a pivotal player in the advancement of medical science and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, Zhejiang, China
Patients applied
Trial Officials
Jianzhen Shan
Principal Investigator
Zhejiang University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported